Objective: To determine whether, and to what degree, preclinical Alzheimer disease (AD) confounds studies of healthy aging where "healthy" is based on cognitive normality alone.
Healthy aging is associated with decreased functional connectivity, as measured by resting-state functional MRI (rs-fMRI). [1] [2] [3] [4] However, previous studies of aging have not controlled for undiagnosed preclinical Alzheimer disease (AD). AD is of particular interest because it is very prevalent in older individuals 5 and has reliable CSF and imaging biomarkers. 6 Nevertheless, prior rs-fMRI studies of aging have not excluded participants with such biomarkers, thereby potentially confounding the effects of aging and preclinical disease. A predictable consequence of this confound would be overestimation of the effects of "healthy aging." It is important to recognize that amyloid deposition disrupts default mode network (DMN) functional connectivity in cognitively normal individuals. [7] [8] [9] [10] Moreover, an APOE e4 allele, a strong AD risk factor, disrupts functional connectivity in the DMN and the salience network (SAL). [11] [12] [13] Previous studies have reported decreased functional connectivity within the DMN in advanced age. [1] [2] [3] [4] Critically, the DMN is also affected in AD. 14 In addition, other resting-state networks (RSNs), including the SAL, are frequently implicated in aging and dementia, including AD. 15, 16 Despite compelling evidence of this confound, less than half of recent aging studies acknowledge it and none address it (see appendix e-1 on the Neurology ® Web site at Neurology.org). The goal of this study is to explicitly demonstrate the magnitude and topography of this confound. To frame our analysis in quantitative terms, we cross-sectionally estimate the effect of age in rs-fMRI measures in subjects with and without CSF evidence of preclinical AD. METHODS Subjects. Participants were drawn from studies of aging and dementia at the Knight Alzheimer's Disease Research Center at Washington University in St. Louis. Participants were community-dwelling volunteers who consented to clinical examination, lumbar puncture, and imaging studies. Inclusion criteria for this study were cognitive normality as defined by a Clinical Dementia Rating (CDR) of zero 17 and additional testing (including lumbar puncture and neuroimaging) performed within 1 year of CDR evaluation. These participants did not present with objective memory problems and underwent lumbar puncture and imaging for strictly research purposes.
Standard protocol approvals, registrations, and patient consents. All studies were approved by the Washington University School of Medicine Human Research Protection Office. Informed consent was obtained from all participants. A subset of these participants was included in previous studies. 16, 18, 19 Lumbar puncture and CSF analysis. CSF was assayed for b-amyloid 1-42 (Ab42) and tau as previously described (see appendix e-1). CDR0 participants who were Ab421 only or Ab421 and tau1 (National Institute on Aging preclinical stages 1 and 2, respectively 20,21 ) were classified as CDR01, while those with normal CSF biomarkers were classified as CDR02. Participants who were CSF Ab422, tau1 21 were not studied.
Imaging acquisition, preprocessing, and quality assurance. Functional and structural imaging as well as initial preprocessing was performed as previously described, 16 but modified to avoid recently described biases. 22 Reduction of head motion artifact was accomplished by regression of the time series derived by retrospective realignment, and nuisance regressors extracted from white matter, CSF, and the global signal. In addition, high movement frames were excluded from functional connectivity analyses (see appendix e-1 for details and summary statistics).
Volumetric data. Estimates of total gray matter volume were calculated using FreeSurfer (http://surfer.nmr.mgh.harvard. edu). 23 The total gray matter value was calculated as the volume of the FreeSurfer-derived gray matter mask. Total gray matter volume was used as a regressor of no interest in the statistical analyses. This measure is not spatially specific and accounts only for global atrophy.
Statistical analyses. This analysis is principally concerned with identifying sets of voxels where the size of the aging effect varies depending on biomarker status (CDR02 vs CDR01). We investigated 2 seed regions: the posterior cingulate cortex (PCC) representing the DMN and the dorsal anterior cingulate cortex representing the SAL. We fit the following model at each voxel:
where z(r) s indicates the Fisher z-transformed correlation between a seed region of interest (ROI) and 1 voxel in subject s. G is a binary variable representing biomarker status (CDR02, CDR01). Model parameters included the voxelwise mean over subjects, m, and regression coefficients (b) estimating the effects of FreeSurferderived gray matter volume, age, biomarker status, and the interaction of age and biomarker status. For the effect of interest (age by biomarker status), parametric volumes of F and p statistics were computed. These maps were voxelwise thresholded at p , 0.01 and cluster thresholded at a corrected p , 0.01. 24 Voxelwise significance was determined from the linear model. Cluster-wise significance was determined by simulating the null hypothesis (no CDR02 vs CDR01 difference) using permutation resampling. Thus, over 1,000 resamplings, the size of clusters surpassing a range of voxelwise b age thresholds was systematically tabulated. [25] [26] [27] The critical F was 4.2 and the critical cluster size was 95 voxels. We then extracted mean b age corresponding to the CDR02 and CDR01 groups in voxels within significant clusters.
Statistical analyses: Composite scores. The previous analyses
focused on relationships between ROIs and voxels. We have previously defined composite scores as measures of RSN integrity based on correlations averaged over ROI pairs within and between networks. 16 These measures are calculated by evaluating z(r) between a priori defined region pairs and averaging these quantities over all ROI pairs within a given RSN. In the present analyses, composite z(r) scores were obtained for 5 RSNs. Examined RSNs included (1) DMN, (2) dorsal attention network (DAN), (3) control network (CON), (4) SAL, and (5) sensorimotor network (SMN). These composite scores were calculated for each participant and subjected to the following model:
where C represents the network composite score (e.g., DMN) in subject s. Composite scores were also calculated across RSNs, e.g., between the DMN and DAN. Across-RSN composite scores are notated, e.g., as DMN-DAN. Comparisons of composite scores were Bonferroni-corrected for multiple comparisons.
RESULTS
Participants. Ages ranged from 45 to 95 years. In study participants, motion-related qualityassurance measures were similar across groups (p . 0.1). The CDR02 (n 5 200) and CDR01 (n 5 97) groups differed slightly in age (table 1) but were well distributed across the age ranges (see appendix e-1, figure e-1). We therefore elected to maintain the larger groups as opposed to reducing the number of participants to perfectly match the groups for age. This allows for the most accurate linear fit of the data (see appendix e-1).
Presence of AD biomarkers modulates age effects in the DMN and SAL. We first investigated the interaction of age and biomarker status on functional connectivity in the DMN and SAL in both CDR02 and CDR01 groups. Figure 1 shows functional connectivity results obtained using the PCC as seed region for the DMN ( figure 1A ) and the dorsal anterior cingulate cortex as seed for the SAL (figure 1B). Significant interactions of age and biomarker status were present across several brain regions, but had similar effects in each significant cluster. In the CDR02 group, the cross-sectional change in functional connectivity per year (b age ) was near 0. In the CDR01 group, these changes were of greater magnitude. In region pairs belonging to the same network (e.g., PCC and medial prefrontal cortex), the change was positive correlations approaching 0 (from above) with age. Conversely, in regions with different network memberships (e.g., PCC and left frontal), the change was negative correlations approaching 0 (from below) with age.
To more quantitatively investigate the interaction of age and the presence of pathology, we identified the significantly affected clusters and extracted the mean b age value in each cluster. Those data are presented in table 2. In each case, the magnitude of the age-related change is larger in the CDR01 group; the multiplicative factor ranges from approximately 4 to 90. To demonstrate this graphically, we extracted the mean Fisher z-transformed correlation coefficient within each cluster for each subject and plotted them against their age (figure 2). It is graphically apparent that the slope of the age vs functional connectivity regression line is steeper in the CDR01 group compared with the CDR02 group.
Size of aging effects in CDR02 is small in regions with interaction. The previous results (figure 2) suggest that the remaining effect of age after accounting for preclinical AD is small. We sought to determine whether these changes were statistically distinguishable from the null hypothesis that functional connectivity in these regions does not change with age. The value of b age in the CDR02 group for each significant cluster is plotted with the 95% confidence interval of that estimate (figure e-2). It is important to note that for most of these clusters, the estimate of the slope of the functional connectivity vs age line overlaps zero, indicating the inability to demonstrate an effect of age, once the effects of preclinical AD are excluded in this set of regions.
Age-related decline in multiple RSNs. The analyses described so far focused on rs-fcMRI effects within the DMN and SAL, which were studied based on previous literature. To test whether other networks were similarly affected, we calculated RSN composite scores for the 5 previously reported RSNs 16 and determined the effect of age and presence of pathology (or an interaction) on composite scores (equation 2). We found significant interactions of age and biomarker status in the DMN and DAN, but not in the other networks (table 3) . It is likely that the SAL does not show a significant interaction at the composite score level because the interaction effect is focused in only a few brain regions and does not survive averaging over a priori RSN definitions. The CON, SAL, and SMN showed effects of age alone, but no significant age by biomarker status interaction. Age-related declines between RSNs. Previous work suggests that large-scale neural dysfunction can manifest as altered across-RSN functional connectivity. 16 To determine whether age by biomarker status interaction effects were also manifested across RSNs, we tested the model represented in equation 2 using cross-RSN composite scores. We found significant effects of age between the DMN-DAN (F 1,293 5 15.21, p 5 0.00012) but no significant interaction between age and biomarker group (all other p values .0.05).
Supporting analyses. Two analytic decisions potentially affect our results: (1) the use of global signal regression (GSR) as a preprocessing step, and (2) the use of slightly age nonmatched groups. GSR is a potent noise-reduction strategy, 28, 29 but objections have been raised regarding the introduction of bias. In appendix e-1, we replicated the main finding of this report (figure 1) without the use of GSR as a preprocessing step (see appendix e-1, figure e-3) . This result demonstrates that our principal finding is robust to this processing choice, although omitting GSR increases noise.
In the sample presented here, the ages of the CDR02 and CDR01 groups differ significantly, but they span a similar range. To ensure that the reported results are not driven by the mismatch in age, we selected a subset of the CDR02 group that most closely matched the age of the CDR01 group. This significantly reduced the number of subjects in the sample and also reduced statistical power. However, the interaction of age and biomarker status on RSN composite scores in the DMN and DAN demonstrated in table 3 remained significant in the age-matched sample (see appendix e-1, figure e-4, and table e-1). DISCUSSION This study demonstrates that agerelated alterations in functional connectivity of the DMN and SAL are strongly influenced by the presence of CSF biomarkers of AD. In quantitative terms, regression coefficients expressing the age dependence of rs-fcMRI measures were increased by a factor of 4 or more in individuals with AD biomarkers. Given that previous studies have shown that amyloid deposition, as imaged by Pittsburgh compound B (PiB)-PET, is associated with decreased DMN functional connectivity, 7-10 it might be argued that the present results are predictable. Nevertheless, although preclinical AD has been acknowledged as a potential confound in studies of "healthy aging" 30 it is not often taken into account. The data presented here demonstrate that failure to do so results in a significant overestimation of the aging effect in some regions.
The concept of amyloid deposition modulating functional connectivity is not new. Indeed, many studies have investigated the effects of amyloid 10, 31 and APOE e4 12,13 on functional connectivity in cognitively normal older adults. These studies have demonstrated decreased functional connectivity but have not investigated how risk factors interacted with age. One study did present data parametric in age and PiB status 1 ; however, that study did not estimate the effect of age separately for the PiB2 and PiB1 groups. Thus, our study describes the size of the age by amyloid status interaction for the first time. Our findings For each cluster identified in figure 1 , the coordinates and cluster size are shown. For each group, we extracted the mean b age value from each cluster for each group. To demonstrate the size of this effect, we calculated the absolute value of the ratio between the 2 groups.
are consistent with current hypotheses concerning preclinical AD 32 and accelerated aging profiles in symptomatic AD. 33 These biomarker-related increases in age-related changes in functional connectivity may be insufficient to cause cognitive deficits. Alternatively, clinical measures (such as the CDR used here) do not reliably detect subtle derangements of cognition. This work underscores the importance of accounting for both age and amyloid status in studies of aging and dementia. We observed significant interactions between age and biomarker status in the DMN, DAN, and SAL, but found effects of age alone in other RSNs (CON, SMN) and between-RSN (DMN-DAN) Figure 2 The slope of the aging effect is reduced in the CDR02 group Scatterplots for each participant separated according to group (CDR02 vs CDR01). (A) Values averaged across voxels in significant clusters scattered against age of each participant. For each ROI pair (PCC as seed), the slope in the CDR01 (red) group is significantly steeper than the slope in the CDR02 (black) group as determined by a significant interaction of age 3 biomarker status ( functional connectivity. These measures were affected by aging but those effects were not modulated by the presence or absence of AD pathology. We previously reported that the CON and SMN are affected by AD. 16 Here, there was no identifiable effect of biomarker status on either network. Thus, changes in these networks may be a later manifestation of AD. Similar statements apply to between-RSN rs-fcMRI measures.
These results indicate that the effects of aging and early AD are dissociable. Moreover, progressive involvement of RSNs may index progression of the disease. The presence of AD biomarkers significantly increased the size of the aging effect in the DMN, DAN, and SAL. In each case reported here, the magnitude of the age-related effect was larger in the CDR01 group. In fact, the size of the aging effect in many regions was indistinguishable from zero in the CDR02 group. This suggests that in the regions where there is a significant interaction of biomarker status and age, the effect of age alone may be minimal. This is not to say there are not significant effects of aging; indeed, we detected main effects of age with no modulating influence of AD pathology. The goal of this study was not to characterize every age effect. We endeavored to identify sets of brain regions where the effect of age was amplified by the presence of AD pathology.
After the removal of the effects of detectable AD pathology, there remain significant, nonzero effects of age. These changes exist in the absence of cognitive decline or detectable neurodegeneration. While it is possible that these effects represent some nonneural process (e.g., vascular), converging evidence indicates that healthy aging is associated with reorganization of functional networks. [34] [35] [36] However, these inferences are based on studies often confounded by preclinical AD. Future studies on functional reorganization in CDR0 cohorts, screened to exclude preclinical AD, coupled with sensitive neuropsychological assessment, may provide insight into the nature of these changes.
The primary finding of this work is that the failure to account for participants who are in the presymptomatic stages of AD leads to an overestimation of the age effect in functional connectivity measures. We suggest that the increased effect of age in the DMN, DAN, and SAL represents the earliest rs-fcMRI manifestations of AD. Future studies should investigate the prodromal periods of other neurodegenerative diseases, the effects of focal atrophy on these observed effects, and the longitudinal nature of these changes. 
